Presentation (CTI)

OBJECTIVES: This study assessed the cost-utility of the respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine (MV) for disease prevention among Colombian infants.
METHODS: We developed a population-based Markov model to compare RSVpreF MV with no intervention (NI) in Colombian infants. The model evaluated clinical outcomes and economic costs over a 10-year horizon, adopting the perspective of the Colombian healthcare system and applying a 5% annual discount rate. Health states included outpatient visits, inpatient management, and death. We took data on clinical outcomes, utilities, and costs from clinical trials, published literature, PAHO, and national databases. We assumed a vaccine uptake of 86.7% based on maternal influenza immunization program coverage. Prices are in 2024 USD (4,020 COP = 1 USD). We set the willingness-to-pay (WTP) threshold at the per capita GDP ($7,491). Robustness checks included one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA) to evaluate the impact of parameter uncertainty on the results.
RESULTS: RSVpreF MV was cost-effective at a WTP threshold of $7,491 per QALY. Implementation of the vaccine could prevent approximately 38,671 RSV-related cases and generate 1,157 QALYs in the study cohort. The intervention's incremental cost was $4 million, resulting in an ICER of $3,643 per QALY compared to NI. OWSA revealed that results were most sensitive to changes in vaccine effectiveness, costs, and RSV hospitalization rates. PSA indicated a 69.3% probability of cost-effectiveness at the specified WTP threshold. Additionally, including RSVpreF MV would likely lead to significant reductions in severe RSV cases requiring hospitalization, alleviating the economic burden on the healthcare system.
CONCLUSIONS: At PAHO prices, RSVpreF MV represents a cost-effective strategy for the Colombian healthcare system. RSVpreF would substantially reduce RSV-related cases, hospitalizations, and economic costs while improving infant health outcomes. These findings strongly support the inclusion of RSVpreF in national immunization programs to achieve better health and financial benefits.